Preliminary study of novel SRC tyrosine kinase inhibitor and proton therapy combined effect on glioblastoma multiforme cell line: In vitro evaluation of target therapy for the enhancement of protons effectiveness

The aim of this work was to evaluate proton therapy effectiveness in combination with a molecule SRC protein inhibitor for glioblastoma multiforme treatment. The role of this novel compound, Si306, is to interfere with glioblastoma carcinogenesis and progression, creating a radiosensitivity condition. The experiments were performed on U87 human glioblastoma multiforme cell line. Molecule concentrations of 10 mu M and 20 mu M were tested in combination with proton irradiation doses of 2, 4, 10 and 21 Gy. Cell survival evaluation was performed by clonogenic assay. The results showed that Si306 increases the efficacy of proton therapy reducing the surviving cells fraction significantly compared to treatment with protons only. These studies will support the preclinical phase realization, in order to evaluate proton therapy effects and molecularly targeted drug combined treatments.